Radha Rajasingham
,
Credentials
MD

Assistant Professor of Medicine
Biography

Bio

Administrator Info
Name: IDIM Admin
Phone: 612-624-9996
Email: idimdivision@umn.edu
Fax: 612-625-4410
Mail: 689 SE 23rd Avenue
MC2821 Room 4-105
Microbiology Research Facility
Minneapolis, MN 55455

Summary
Dr. Rajasingham is an Infectious Diseases physician and physician-scientist at the University of Minnesota. Her primary research interest is to maximize the public health impact of screening HIV-infected persons for opportunistic infections in order to decrease HIV/AIDS-related mortality. She is particularly interested in the evaluation of cost-effective diagnostics and treatment algorithms to care of persons with advanced HIV disease. Dr. Rajasingham is the co-PI of a phase II randomized clinical trial in Uganda evaluating the safety of high dose AmBisome to prevent cryptococcal meningitis in persons with advanced HIV disease, and PI for an R01 cluster-randomized trial evaluating point-of-care diagnostics in persons with advanced HIV disease, funded by NIAID. 

Research Summary

Dr. Rajasingham is a physician-scientist trained in the clinical practice of infectious diseases. Her research interests span evaluation and cost-effectiveness of point-of-care diagnostics in persons with advanced HIV disease, cryptococcal screening and prevention, and management of cryptococcal meningitis.

Research Projects

  • Evaluation of CRAG Screening with Enhanced Antifungal Therapy for Asymptomatic CRAG-Positive Persons (K23AI138851)
  • An Enhanced Package of Care to Reduce Mortality in Persons with Advanced HIV Disease (R01AI162181)

Clinical Summary

  • HIV/AIDS
  • PREP
  • Global Health

Education

MD, University of Minnesota

Honors and Recognition

Rising Star, Mpls/St. Paul Magazine
2020
Young Physician Scientists Award, American Society for Clinical Investigation
2020
Selected Publications

Selected Publications

Rajasingham R, Meya DB, Greene GS, Jordan A, Nakawuka M, Chiller TM, Boulware DR, Larson BA. Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis. PLoS One. 2019 Jan 10;14(1):e0210105. doi: 10.1371/journal.pone.0210105. PMID: 30629619; PMCID: PMC6328136.,
Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ML, Pullen MF, Nascene AA, Williams DA, Engen NW, Okafor EC, Rini BI, Mayer IA, McDonald EG, Lee TC, Li P, MacKenzie LJ, Balko JM, Dunlop SJ, Hullsiek KH, Boulware DR, Lofgren SM; COVID PREP team. Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. Clin Infect Dis. 2021 Jun 1;72(11):e835-e843. doi: 10.1093/cid/ciaa1571. PMID: 33068425; PMCID: PMC7665393.,
Nalintya E, Meya DB, Lofgren S, Huppler Hullsiek K, Boulware DR, Rajasingham R. A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda. J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):231-238. doi: 10.1097/QAI.0000000000001669. PMID: 29509588; PMCID: PMC5953806.,
Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyse A, Boulware DR. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017 Aug;17(8):873-881. doi: 10.1016/S1473-3099(17)30243-8. Epub 2017 May 5. PMID: 28483415; PMCID: PMC5818156.,